Invivo Therapeutics Holdings Corp (OTC:NVIV) has been constantly jumping up and down lately. After the price jump on 
Tuesday, yesterday the stock fell down again by losing 4.81%, on a rather high traded volume.
The reason for the fast price changes must be the latest news by the company. This week, the company released a couple of positive announcements on its business and managed to encourage traders. However, the inspiration lasted only for a day. Thus, the next move of NVIV remains unpredictable.
What is more interesting though, is that certain members of Invivo’s team have acquired huge amounts of the company’s shares of common stock, which cannot be explained. In any case, these transactions might reflected on NVIV stock price in a positive way.
InVivo Therapeutics Corporation is developing and intends to commercialize technologies for the treatment of spinal cord injuries. The biggest issue facing the company remains its financials, which look disastrous.[BANNER]
Its latest 10-Q is full of huge expenses, enormous operating loss and a shocking deficit accumulated during the development stage period. At the same time, the company’s cash position is not able to cover any of these, while NVIV keeps waiting for an FDA approval for its second product.
The management still believes that its cash will fund the operations through March 31, 2012. However, the team claims that Invivo will need to raise substantial additional capital to complete its projects.
